IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+29.45%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$368M
AUM Growth
+$2.11M
(+0.58%)
Cap. Flow
-$72.5M
Cap. Flow
% of AUM
-19.73%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
127
New
24
Increased
22
Reduced
26
Closed
20
Top Buys
| 1 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$10.9M |
| 3 |
Cytokinetics
CYTK
|
$8.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
| 5 |
Pyxis Oncology
PYXS
|
$7.08M |
Top Sells
| 1 |
argenx
ARGX
|
$26.5M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$21.2M |
| 3 |
SPDR S&P Homebuilders ETF
XHB
|
$19.1M |
| 4 |
Nuvalent
NUVL
|
$11.8M |
| 5 |
Disc Medicine
IRON
|
$10.6M |
Sector Composition
| 1 | Healthcare | 98.68% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
AbbVie
ABBV
$375B
| – | – |
0
| – | – |
|
127
Aclaris Therapeutics
ACRS
$227M
| – | – |
-19,482
| Closed | -$20.5K |
|